JP6575031B2 - モンテルカストナトリウム製剤 - Google Patents
モンテルカストナトリウム製剤 Download PDFInfo
- Publication number
- JP6575031B2 JP6575031B2 JP2015159977A JP2015159977A JP6575031B2 JP 6575031 B2 JP6575031 B2 JP 6575031B2 JP 2015159977 A JP2015159977 A JP 2015159977A JP 2015159977 A JP2015159977 A JP 2015159977A JP 6575031 B2 JP6575031 B2 JP 6575031B2
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- tablet
- granulated product
- coated
- montelukast sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 103
- 229960001951 montelukast sodium Drugs 0.000 title claims description 56
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 title claims description 56
- 238000000034 method Methods 0.000 claims description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 55
- 238000005550 wet granulation Methods 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 37
- 239000011248 coating agent Substances 0.000 claims description 29
- 239000011247 coating layer Substances 0.000 claims description 29
- 238000000576 coating method Methods 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 6
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- 239000003826 tablet Substances 0.000 description 101
- 238000003860 storage Methods 0.000 description 33
- 239000008187 granular material Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- 150000003462 sulfoxides Chemical group 0.000 description 20
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 18
- 229960005127 montelukast Drugs 0.000 description 18
- 238000004806 packaging method and process Methods 0.000 description 16
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 12
- 229910052782 aluminium Inorganic materials 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 8
- 238000013112 stability test Methods 0.000 description 8
- 238000004040 coloring Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229960001681 croscarmellose sodium Drugs 0.000 description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000005498 polishing Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- -1 7-chloro-2-quinolinyl Chemical group 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 239000008199 coating composition Substances 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- XQKRPEDJRVOOAA-UHFFFAOYSA-J [Mg+2].[Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O Chemical compound [Mg+2].[Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XQKRPEDJRVOOAA-UHFFFAOYSA-J 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000007699 photoisomerization reaction Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015159977A JP6575031B2 (ja) | 2014-07-28 | 2015-07-28 | モンテルカストナトリウム製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014153305 | 2014-07-28 | ||
| JP2014153305 | 2014-07-28 | ||
| JP2015159977A JP6575031B2 (ja) | 2014-07-28 | 2015-07-28 | モンテルカストナトリウム製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019122670A Division JP7093752B2 (ja) | 2014-07-28 | 2019-07-01 | モンテルカストナトリウム製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016033133A JP2016033133A (ja) | 2016-03-10 |
| JP2016033133A5 JP2016033133A5 (enrdf_load_stackoverflow) | 2018-08-02 |
| JP6575031B2 true JP6575031B2 (ja) | 2019-09-18 |
Family
ID=55452210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015159977A Active JP6575031B2 (ja) | 2014-07-28 | 2015-07-28 | モンテルカストナトリウム製剤 |
| JP2019122670A Active JP7093752B2 (ja) | 2014-07-28 | 2019-07-01 | モンテルカストナトリウム製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019122670A Active JP7093752B2 (ja) | 2014-07-28 | 2019-07-01 | モンテルカストナトリウム製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6575031B2 (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017001989A (ja) * | 2015-06-11 | 2017-01-05 | ニプロ株式会社 | 医薬組成物の製造方法及び医薬組成物 |
| CN108057021B (zh) * | 2017-12-25 | 2019-03-19 | 南京康舟医药科技有限公司 | 一种孟鲁斯特钠颗粒剂及其制备方法 |
| JPWO2020111089A1 (ja) * | 2018-11-27 | 2021-10-14 | 協和キリン株式会社 | 医薬組成物 |
| CN112386578B (zh) * | 2020-10-26 | 2022-11-22 | 石药集团欧意药业有限公司 | 一种孟鲁司特钠咀嚼片及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090124657A1 (en) | 2007-08-14 | 2009-05-14 | Ramesh Kappala | Pharmaceutical compositions comprising montelukast |
| WO2009153305A2 (en) | 2008-06-19 | 2009-12-23 | Sandoz Ag | Pharmaceutical compositions of montelukast sodium |
| US20110189274A1 (en) | 2008-10-06 | 2011-08-04 | Swati Mukherjee | Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates |
| KR20130009553A (ko) * | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
| KR101418404B1 (ko) * | 2012-01-06 | 2014-07-10 | 한미약품 주식회사 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제 |
| CN103239450B (zh) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法 |
| JP5858486B2 (ja) * | 2012-05-11 | 2016-02-10 | 塩野義製薬株式会社 | アスコルビン酸、スクラロースおよびアスパルテームを含有する固形製剤 |
| CN103494785B (zh) | 2013-10-09 | 2015-03-11 | 福建华海药业有限公司 | 一种孟鲁司特钠咀嚼片及其制备方法 |
-
2015
- 2015-07-28 JP JP2015159977A patent/JP6575031B2/ja active Active
-
2019
- 2019-07-01 JP JP2019122670A patent/JP7093752B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016033133A (ja) | 2016-03-10 |
| JP2019156857A (ja) | 2019-09-19 |
| JP7093752B2 (ja) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7093752B2 (ja) | モンテルカストナトリウム製剤 | |
| JP5365777B2 (ja) | 光に対して安定なラモセトロンの固形医薬組成物 | |
| JP6183979B2 (ja) | アリピプラゾール無水物を含有する固形製剤の製造方法 | |
| TW202313027A (zh) | 樂伐替尼（Ｌｅｎｖａｔｉｎｉｂ）調配物 | |
| AU2006213439A1 (en) | Pharmaceutical composition of acid labile substances | |
| JP5270798B1 (ja) | アゾセミドを有効成分とするコーティング製剤 | |
| TW201717937A (zh) | 含有芳基烷基胺化合物之醫藥組合物 | |
| WO2015069203A1 (en) | Capsule comprising rupatadine fumarate and montelukast sodium | |
| WO2020111089A1 (ja) | 医薬組成物 | |
| JP4874797B2 (ja) | フィルムコーティング錠 | |
| WO2005099698A1 (ja) | 安定化された４－アミノ－５－クロロ－Ｎ－［（１Ｒ，３ｒ，５Ｓ）－８－メチル－８－アザビシクロ［３．２．１］オクタ－３－イル]－２－［１－メチルブタ－２－インイルオキシ］ベンズアミド含有組成物 | |
| JP2020029447A (ja) | 腸溶性高分子及び抗付着剤を含有する顆粒 | |
| BRPI0621739A2 (pt) | formulação estável que consiste em drogas sensìveis à umectação e seu procedimento de fabricação | |
| JP7515533B2 (ja) | デスロラタジン含有フィルムコーティング錠剤 | |
| JP6133073B2 (ja) | ループ利尿薬を有効成分とする医薬製剤 | |
| EP3251669B1 (en) | Solid composition of pyrrole carboxamide | |
| JP6336651B1 (ja) | 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤 | |
| JP6339800B2 (ja) | ミグリトール含有コーティング製剤 | |
| JP2020066634A (ja) | 腸溶性高分子及び崩壊剤を含有する顆粒 | |
| JP2025073688A (ja) | ボスチニブ医薬製剤 | |
| JP2022024813A (ja) | アキシチニブ（ｉｖ型）を有効成分とする医薬錠剤及び包装された医薬錠剤 | |
| HK1247826B (en) | Solid composition of pyrrole carboxamide | |
| TR201719919A2 (tr) | The pharmaceutical combination comprising raloxifene and aripiprazole | |
| JP2017075172A (ja) | 安定性が改善された、アリピプラゾールを含有する散剤 | |
| HK1179534B (en) | Coated preparation containing azosemide as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20150908 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150911 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180620 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180620 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190604 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190701 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190731 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6575031 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6575031 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |